Current treatment options for <i>Mycobacterium marinum</i> cutaneous infections

Medel-Plaza, Marina; Esteban, Jaime

doi:10.1080/14656566.2023.2211258

Cited by 5 publications

(4 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, the Mycobacterium marinum infected zebrafish model is promising, because M. marinum has a close genetic relationship with M. tuberculosis . However, it has the advantage that it can actually grow within a week ( Medel-Plaza and Esteban, 2023 ). In addition, M. marinum has similar pathogenic mechanisms to M. tuberculosis , such as the formation of granuloma.…”

Section: Treatmentmentioning

confidence: 99%

“…In addition, M. marinum has similar pathogenic mechanisms to M. tuberculosis , such as the formation of granuloma. However, the bottleneck to establish such a model is that there is no documented information about bacteriophages that are specific against M. marinum infections yet ( Rybniker et al, 2006 ; Drakou et al, 2020 ; Medel-Plaza and Esteban, 2023 ). This might be due to an intracellular inhibition of phage replication in M. marinum , since shuttle phasmids based on some phages are able to transfect M. marinum ( Rybniker et al, 2003 , 2006 ).…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Mycobacteriophages in diagnosis and alternative treatment of mycobacterial infections

Ouyang,

Li,

Song

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

Antimicrobial resistance is an increasing threat to human populations. The emergence of multidrug-resistant “superbugs” in mycobacterial infections has further complicated the processes of curing patients, thereby resulting in high morbidity and mortality. Early diagnosis and alternative treatment are important for improving the success and cure rates associated with mycobacterial infections and the use of mycobacteriophages is a potentially good option. Since each bacteriophage has its own host range, mycobacteriophages have the capacity to detect specific mycobacterial isolates. The bacteriolysis properties of mycobacteriophages make them more attractive when it comes to treating infectious diseases. In fact, they have been clinically applied in Eastern Europe for several decades. Therefore, mycobacteriophages can also treat mycobacteria infections. This review explores the potential clinical applications of mycobacteriophages, including phage-based diagnosis and phage therapy in mycobacterial infections. Furthermore, this review summarizes the current difficulties in phage therapy, providing insights into new treatment strategies against drug-resistant mycobacteria.

show abstract

Section: Treatmentmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

Mycobacteriophages in diagnosis and alternative treatment of mycobacterial infections

Ouyang,

Li,

Song

et al. 2023

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…The social dimension and cultural aspects in the regions concerned also affect the chances of treatment success [ 13 , 14 ]. Cost, the availability of treatments, and, in particular, the need for compliance over such long periods of therapy are major obstacles that affect the chances of achieving a satisfactory outcome [ 3 , 4 , 15 ]. Recovery is slow and the recurrence of infection is common [ 2 , 3 , 16 ].…”

Section: Introductionmentioning

confidence: 99%

Formulation and Stability of a 1% Clarithromycin-Based Topical Skin Cream: A New Option to Treat Buruli Ulcers?

Sebti,

Schweitzer-Chaput,

Cisternino

et al. 2024

Pharmaceuticals

View full text Add to dashboard Cite

There are more than 170 known species of non-tuberculous mycobacteria, and some are responsible for serious diseases in people infected with them. One of these is Buruli ulcers, a neglected tropical disease endemic in more than 33 countries and caused by Mycobacterium ulcerans, which infects skin tissue. Treatment consists of a long-term regimen combining the use of oral rifampin with another anti-tuberculosis drug (e.g., clarithromycin). Patients in these countries face difficulties in accessing and adhering to this therapy. This study investigates the feasibility of formulating stable, optimized clarithromycin as a topical cutaneous cream. The cream was formulated, and its stability was evaluated under different storage temperature conditions and using a stability indicator method. The results showed that the clarithromycin cream was stable for at least 60 days, even at extreme temperatures (40 °C). In conclusion, the data presented here demonstrate the stability of a new form of topical cutaneous clarithromycin, which may offer a new approach to the treatment of Buruli ulcers and clarithromycin-sensitive infections.

show abstract

“…One approach to improving the efficacy of single-drug therapy has been to design treatment regimens based on the pharmacodynamics of antibiotics through controlled release and improving intracellular targeting (Hussain et al, 2019). Current treatments for M. marinum infections include streptomycin and gentamicin, with doxycycline as an emerging alternative therapy (Medel-Plaza and Esteban, 2023). Resistance of Mycobacterium species to individual drugs is common, with some cases of tuberculosis in humans requiring lengthy treatment regimens involving potent multi-drug treatments (Hussain et al, 2019;Bendre et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Nanotherapeutic delivery of antibiotic cocktail enhances intra-macrophage killing of Mycobacterium marinum

et al. 2023

View full text Add to dashboard Cite

Mycobacterium marinum is a waterborne pathogen responsible for tuberculosis-like infections in cold-blooded animals and is an opportunistic pathogen in humans. M. marinum is the closest genetic relative of the Mycobacterium tuberculosis complex and is a reliable surrogate for drug susceptibility testing. We synthesized and evaluated two nanoparticle (NP) formulations for compatibility with rifampicin, isoniazid, pyrazinamide, and ethambutol (PIRE), the front-line antimycobacterial drugs used in combination against active tuberculosis infections. Improved in vitro antimicrobial activity was observed with encapsulated rifampicin alone or in a cocktail of drugs formulated through co-encapsulation in amphiphilic polyanhydride NPs. Broth antimicrobial testing revealed that the encapsulation of PIRE in NP resulted in a significant increase in antimicrobial activity, with the benefit over soluble formulations at biologically relevant concentrations ranging from >10 to >3,000 fold. M. marinum-infected human macrophages treated with NP-PIRE were cleared of viable bacteria in 48 h following a single treatment, representing a >4 log reduction in colony-forming units and a >2,000-fold increase in antimicrobial activity. The amphiphilic polyanhydride nanoparticles demonstrated the ability to co-encapsulate PIRE antibiotics and enhance their antimicrobial activity against M. marinum in infected macrophages in culture and in vitro. These data suggest that polyanhydride nanoparticles are a promising nanotherapeutic for combatting Mycobacterium infections through improved intracellular targeting of encapsulated antibiotics.

show abstract

Current treatment options for Mycobacterium marinum cutaneous infections

Cited by 5 publications

References 75 publications

Mycobacteriophages in diagnosis and alternative treatment of mycobacterial infections

Mycobacteriophages in diagnosis and alternative treatment of mycobacterial infections

Formulation and Stability of a 1% Clarithromycin-Based Topical Skin Cream: A New Option to Treat Buruli Ulcers?

Nanotherapeutic delivery of antibiotic cocktail enhances intra-macrophage killing of Mycobacterium marinum

Contact Info

Product

Resources

About